Weight Management

Eloralintide

LY3841136 · Lilly eloralintide

Eli Lilly investigational long-acting amylin receptor agonist (eloralintide / LY3841136). Not amycretin. Not petrelintide. Not a compounded amylin cake.

Not FDA-approved - research chemical
Reviewed by CalcMyPeptide Editorial Team
Last updated: September 2026Evidence: Emerging
Typical research dose
Investigational - sponsor protocol only
Frequency
Trial schedules only
Half-life
Long-acting program (sponsor PK)
Common vials
N/A (oral)

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

  • Metabolic / weight5.5/10

    Lilly amylin program. Haircut: investigational; not amycretin; not a cake.

Compound card

Sequence
Long-acting amylin agonist (LY3841136 / eloralintide)
Class
Investigational long-acting amylin receptor agonist (Eli Lilly)
Formula
Amylin analog (proprietary)
Status
Not FDA-approved · research use

How it works

Eloralintide (LY3841136) is Eli Lilly’s investigational long-acting amylin receptor agonist. Mechanism class matches the amylin satiety story; it is not amycretin (dual amylin/GLP-1), not petrelintide, and not pramlintide.

Source: Eli Lilly clinical program disclosures; not a finished US label

Research Use Cases

  • ✓Amylin pipeline literacy: Moderate
  • ✓DIY reconstitution: Low

Dosing

PhaseDoseFrequencyNotes
Human careSponsor protocol onlyTrial scheduleNot a DIY titration.
Research-chem SKUDo not inventn/aNo honest cake chart.

Administration

Route / form
Parenteral under clinical protocol
Timing
Program-defined
Empty stomach?
No - Food timing is not critical.

Timeline

Trial programs
Sponsor-owned endpoints only.

Who it is for

Amylin pipeline literacy

Moderate

Name disambiguation vs amycretin matters.

DIY reconstitution

Low

Wrong tool.

Safety & Considerations

Investigational amylin-class GI risk. Unverified vials are identity risk. Clinical stacking with insulin is a clinician problem, not a forum protocol.

Regulatory & Legal Status

FDA Status (US)
Research Only
WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

  • Not amycretin (dual amylin/GLP-1).
  • Not petrelintide or cagrilintide.
  • Sponsor protocols ≠ research-chem doses.
  • This site will not treat obesity from this leaf.

Verdict

Eloralintide is Lilly’s long-acting amylin agonist. Not amycretin. Not petrelintide. Not a compounded amylin cake.

Interactions & Contraindications

Investigational amylin-class GI risk. Unverified vials are identity risk. Clinical stacking with insulin is a clinician problem, not a forum protocol.

Frequently Asked Questions

Is eloralintide amycretin?▼
No. Amycretin is dual amylin/GLP-1. Eloralintide is an amylin-pathway agonist program.
Is there a reconstitution example?▼
Not an honest one for gray-market fill. Skip the calculator.

📚 Related Articles

GLP-1 Dose Escalation Guide: Semaglutide, Tirzepatide & Retatrutide
14 min read • Pillar Guide

Looking for a trusted source? See our recommended suppliers

Independently tested · COA-verified · Save 10% with our exclusive code

See suppliers →
← Back to Peptide Library